For research use only. Not for therapeutic Use.
Luseogliflozin (TS 071) is a potent, selective, orally active sodium-dependent glucose cotransporter (SGLT) 2 inhibitor, with an IC50 of 2.26 nM, about 1765-fold selectivity over SGLT1 (IC50, 3990 nM). Luseogliflozin has the protential for researching type 2 diabetes.
Luseogliflozin (TS-071, 3p) is a potent sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor, with an IC50 of 2.26 nM, about 1765-fold selectivity over SGLT1 (IC50, 3990 nM); Luseogliflozin has the protential for treating type 2 diabetes[1].
Luseogliflozin (1 mg/kg, p.o.) exhibits a blood glucose lowering effect, excellent urinary glucose excretion properties, and promising PK profiles in rats and dogs[1].
| Catalog Number | R030012 |
| CAS Number | 898537-18-3 |
| Synonyms | (3R,4R,5S,6R)-2-[5-[(4-ethoxyphenyl)methyl]-2-methoxy-4-methylphenyl]-6-(hydroxymethyl)thiane-3,4,5-triol |
| Molecular Formula | C23H30O6S |
| Purity | ≥95% |
| InChI | InChI=1S/C23H30O6S/c1-4-29-16-7-5-14(6-8-16)10-15-11-17(18(28-3)9-13(15)2)23-22(27)21(26)20(25)19(12-24)30-23/h5-9,11,19-27H,4,10,12H2,1-3H3/t19-,20-,21+,22-,23?/m1/s1 |
| InChIKey | WHSOLWOTCHFFBK-HZQGQDIUSA-N |
| SMILES | CCOC1=CC=C(C=C1)CC2=CC(=C(C=C2C)OC)C3C(C(C(C(S3)CO)O)O)O |
| Reference | [1]. Kakinuma H, et al. (1S)-1,5-anhydro-1-[5-(4-ethoxybenzyl)-2-methoxy-4-methylphenyl]-1-thio-D-glucitol (TS-071) is a potent, selective sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for type 2 diabetes treatment. J Med Chem. 2010 Apr 22;53(8):3247-61. |
